FindTrial
Sign In

Terlipressin in liver failure

Safety of terlipressin in patients with acute on chronic liver failure-an observational study. - TerliACLF

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2019/10/021737
Enrollment
100
Registered
2019-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K729- Hepatic failure, unspecified

Interventions

Intervention1: Terlipressin: ACLF patients receiving terlipressin for variceal bleed, shock or kidney injury will be recruited

Sponsors

No sponsor required
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Acute on chronic liver patients (as per APASL criteria) aged between 18-75years who are receiving terlipressin injection will be included. Baseline clinical, demographic and biochemical data will be recorded.

Exclusion criteria

Exclusion criteria: Refusal to participate

Design outcomes

Primary

MeasureTime frame
Incidence of adverse eventsTimepoint: 14 days—

Secondary

MeasureTime frame
Efficacy of terlipressin in esophageal variceal bleedTimepoint: day 14;Efficacy of terlipressin in HRSTimepoint: day 14;Predictors of terlipressin non-response.Timepoint: day 14;Transplant-free survival at day 30, 90.Timepoint: day 30—

Countries

India

Contacts

Public ContactAnand Kulkarni

AIG Hospital

anandvk90@gmail.com08553322434

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 17, 2026